Gain Therapeutics, Inc. (GANX) NASDAQ
$1.49 0.22 (17.32%)
Market Cap: $38.05M
As of 09/11/24 04:00 PM EDT. Market closed.
Gain Therapeutics, Inc. (GANX)
NASDAQ
$1.49
0.22 (17.32%)
Market Cap: $38.05M
As of 09/11/24 04:00 PM EDT. Market closed.
Add to Portfolio
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore ... read more
COMPANY PROFILE
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Gene Mack M.B.A.
Full Time Employees
29
CEO Compensation (Base)
$500,000
CEO Compensation (Total)
$1.51M
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Gene Mack M.B.A.
Full Time Employees
29
CEO Compensation (Base)
$500,000
CEO Compensation (Total)
$1.51M
Address
4800 Montgomery Lane, MD, Bethesda, 20814.
PRICE CHART FOR GAIN THERAPEUTICS, INC.
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$1.16
Previous Close
$1.27
Days Range
$1.16 - $1.56
52 week range
$0.89 - $5.33
Volume
642,122
Avg. Volume (30 days)
424,441
Market Cap
$38.05M
Dividend Yield
-
P/E
(1.14)
Shares Outstanding
25,535,500
Open
$1.16
Previous Close
$1.27
Days Range
$1.16 - $1.56
52 week range
$0.89 - $5.33
Volume
642,122
Avg. Volume (30 days)
424,441
Market Cap
$38.05M
Dividend Yield
-
P/E
(1.14)
Shares Outstanding
25,535,500
FINANCIAL STATEMENTS FOR GAIN THERAPEUTICS, INC.
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR GAIN THERAPEUTICS, INC.
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Mack Gene | CFO and Interim CEO | Aug 09, 2024 | Buy | $1.01 | 14,400 | 14,544 | 14,400 | Aug 12, 2024, 05:23 PM |
| Islam Khalid | Executive Chairman | Aug 09, 2024 | Buy | $1.00 | 50,000 | 49,940 | 50,000 | Aug 12, 2024, 05:23 PM |
| RICHMAN ERIC I | Director | Jul 01, 2024 | Buy | $1.22 | 17,000 | 20,670 | 289,629 | Jul 01, 2024, 05:00 PM |
| Riley Jeffrey Scott | Director | Mar 28, 2024 | Buy | $3.86 | 30,000 | 115,770 | 30,000 | Apr 01, 2024, 04:01 PM |
| Alder Matthias | Chief Executive Officer | Mar 26, 2024 | Option Exercise | $4.06 | 6,085 | 24,705 | 21,140 | Mar 28, 2024, 09:00 PM |
| Alder Matthias | Chief Executive Officer | Dec 21, 2023 | Sale | $2.46 | 206 | 507 | 5,286 | Dec 22, 2023, 04:17 PM |
| Alder Matthias | Chief Executive Officer | Dec 07, 2023 | Sale | $2.50 | 1,820 | 4,550 | 4,855 | Dec 14, 2023, 04:01 PM |
| RICHMAN ERIC I | CHIEF EXECUTIVE OFFICER | May 25, 2022 | Buy | $2.58 | 2,482 | 6,404 | 217,729 | May 27, 2022, 04:10 PM |
| RICHMAN ERIC I | CHIEF EXECUTIVE OFFICER | May 20, 2022 | Buy | $2.83 | 9,256 | 26,194 | 215,247 | May 23, 2022, 04:41 PM |
| RICHMAN ERIC I | CHIEF EXECUTIVE OFFICER | May 19, 2022 | Buy | $2.71 | 4,000 | 10,840 | 205,991 | May 23, 2022, 04:41 PM |
| Calabrese Salvatore | CHIEF FINANCIAL OFFICER | May 19, 2022 | Buy | $2.70 | 3,000 | 8,100 | 3,000 | May 23, 2022, 04:00 PM |
| Calabrese Salvatore | CHIEF FINANCIAL OFFICER | May 19, 2022 | Buy | $8100.00 | 3,000 | 24,300,000 | 8,100 | May 19, 2022, 05:00 PM |
| RICHMAN ERIC I | Chief Executive Officer | Aug 16, 2021 | Buy | $7.87 | 4,922 | 38,716 | 216,820 | Apr 21, 2022, 04:50 PM |
| RICHMAN ERIC I | Director | Aug 16, 2021 | Option Exercise | $7.87 | 4,922 | 38,716 | 216,820 | Aug 17, 2021, 09:03 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| Mack Gene | CFO and Interim CEO | 08/09/2024 | 14,544 |
| Islam Khalid | Executive Chairman | 08/09/2024 | 49,940 |
| RICHMAN ERIC I | Director | 07/01/2024 | 20,670 |
| Riley Jeffrey Scott | Director | 03/28/2024 | 115,770 |
| Alder Matthias | Chief Executive Officer | 03/26/2024 | 24,705 |
| Alder Matthias | Chief Executive Officer | 12/21/2023 | 507 |
| Alder Matthias | Chief Executive Officer | 12/07/2023 | 4,550 |
| RICHMAN ERIC I | CHIEF EXECUTIVE OFFICER | 05/25/2022 | 6,404 |
| RICHMAN ERIC I | CHIEF EXECUTIVE OFFICER | 05/20/2022 | 26,194 |
| RICHMAN ERIC I | CHIEF EXECUTIVE OFFICER | 05/19/2022 | 10,840 |
| Calabrese Salvatore | CHIEF FINANCIAL OFFICER | 05/19/2022 | 8,100 |
| Calabrese Salvatore | CHIEF FINANCIAL OFFICER | 05/19/2022 | 24,300,000 |
| RICHMAN ERIC I | Chief Executive Officer | 08/16/2021 | 38,716 |
| RICHMAN ERIC I | Director | 08/16/2021 | 38,716 |
Load More Insider Transactions
FUNDS WITH A POSITION IN GAIN THERAPEUTICS, INC.
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | 183,736 | 0.00002% | 3.75% | Other |
| RENAISSANCE TECHNOLOGIES LLC | 118,700 | 0.00026% | 154.18% | Other |
| BLACKROCK INC. | 84,620 | 0% | 12.23% | Other |
CHANGE IN SHARES OUTSTANDING FOR GAIN THERAPEUTICS, INC.
STOCK BUYBACKS FOR GAIN THERAPEUTICS, INC.
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 03/31/2024
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
12/31/2023
19.71%
1Q
12/31/2022
51.30%
5Q
09/30/2022
51.30%
6Q
06/30/2022
51.30%
7Q
03/31/2022
51.30%
8Q
12/31/2021
51.08%
9Q
09/30/2021
51.38%
10Q
06/30/2021
51.38%
11Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR GAIN THERAPEUTICS, INC.
LOADING...